Dr. Ken-ichi Arai received his M.D. degree in 1967 from Faculty of Medicine, the University of Tokyo and Ph. D. degree in Biochemistry in 1974 from Department of Chemistry, Institute of Medical Science, University of Tokyo. He became a Instructor of Chief of Department of Chemistry, Institute of Medical Science, University of Tokyo in 1974, a Fellow of Department of Biochemistry, Stanford University School of Medicine (1977-1980). After this position, Dr. Arai held the positions of Director in Molecular Biology of DNAX Research Institute of Molecular and Cellular Biology, U.S.A. (1981-1990), Professor of Department of Molecular and Developmental Biology, Institute of Medical Science, University of Tokyo (1989-present), and Distinguished Visiting Scientist of DNAX Research Institute of Molecular and Cellular Biology, U.S.A. (1990-present). His professional specificity is Biochemistry, Molecular Biology (Enzyme mechanism of DNA replication, gene expression, and signal transduction), Molecular Immunology and Hematology. He also serves as editorial board of several international journals.

Dr. Kaixian Chen is a member of Chinese Academy of Sciences and the President of Shanghai Institute of Pharmaceutical Research; He graduated from physics department, Fudan University in 1967. He received his doctor's degree in Shanghai Institute of Materia Medica in 1985 and did his postdoctor's research at the Institute of biophysics and biochemistry at Paris. He is currently member of expert committee for National New Drug Research and Development Program.

Dr. Zhu Chen is the Vice President of Chinese Academy of Sciences, and member of the Chinese Academy of Sciences. He is also the director of Shanghai Institute of Hematology, at Ruijin Hospital and Chinese National Human Genome Center at Shanghai. He obtained his D.Sc. at the University Paris VII, France, conducting genetic research in hematology. As a coordinator of the Human Genome Project (HGP) in China, he played key role in organizing the Chinese human genome society. He is also the Chief Scientist of the Chinese National Hi-Tech Development Program.

Dr. Lewis L. Lanier is a professor of the Microbiology/Immunology Department and Cancer Research Institute of UCSF. Dr. Lanier received his Ph.D. in Immunology from University of North Carolina, Chapel Hill in 1978, and later finished his post-doctoral training at University of New Mexico. He then joined Becton Dickinson as a senior scientist and became a key member in setting up BD's monoclonal antibody business. He was an associate director in Becton Dickinson Immunocytometry Systems before he moved to DNAX Research Institute in 1991. At DNAX, he held various titles such as Senior Scientific Staff, Associate Director, and Director of Immunobiology. In 1999, he joined University of California, San Francisco as a faculty member. Dr. Lanier has made many seminal discoveries in the areas of natural immunity and tumor immunology. He is on the editorial board of several major immunology journals, and is currently the councilor of the American Association of Immunologists.

Prof. Yong-Jun Liu is an internationally known expert in tumor immunology. He is the chairman of Immunology Department of MD Anderson Cancer Center at The University of Texas. He obtained his M.D. degree from Norman Bethune University School of Medicine in China and his Ph.D. from the Department of Immunology, Birmingham School of Medicine in the United Kingdom. He did immunology research at the pharmaceutical company Schering-Plough in France and later joined the biotech company DNAX 1997. He is a member of the New York Academy of Sciences and the American Association for Immunology. He has more than 100 publications in Journals like Science, Nature and Immunity. He’s considered a leader in the field of tumor immunology.

Dr. Yixue Li is the Director of Bioinformatics Center of Shanghai Institute for Biological Science, and Chair of the expert committee for the Bioinformatics Technology Section of Chinese National Hi-Tech Development Program. In 1996, he received the doctor's degree of physics at Heidelberg University, Germany. From 1997 to 2000, he continued his research work in biophysics field at European Molecular Biology Lab (EMBL).

Dr. Xinyu Qin is the Vice President of Shanghai Zhong Shan Hospital.He finished his medical school in Shanghai Second Medical University,and then received his MS degree in Shanghai Medical University.He later went to Great Britain and received his Ph.D. degree from London University in 1988.He serves on the advisory board of many scientific organizations,and is member of the editorial board of several clinical research journals.As a surgeon.Dr. Qin is an expert in cancer therapy.

Dr. Thomas A. Raffin is the Professor and Chief (1991) of the Division of Pulmonary and Critical Care Medicine at Stanford University Medical Center. He is also the Co-Founder (1989) and Co-Director of the Stanford University Center for Biomedical Ethics. Dr. Raffin was honored with the Colleen and Robert Haas Professorship in Medicine and Biomedical Ethics in 1999. He graduated from Stanford University in 1968 and later received his MD from Stanford University School of Medicine. He completed his internship and residency at the Peter Bent Brigham Hospital in Boston and returned to Stanford as a fellow in pulmonary and critical care medicine. He joined the clinical faculty at Stanford in 1980. He is a cofounder of Rigel Pharmaceuticals, and is also on the scientific advisory board of many biotech companies.

Professor Binggen Ru is a professor of Department of Biochemistry of Beijing University, in charge of the protein structure & function research in the National Laboratory of Protein Engineering and Plant Gene Engineering. He graduated from Beijing University with a master degree in 1965. During 1983-1985 he is a visiting scholar in the department of biochemistry, the State University of New York. He currently serves on panel of State Drug Administration (Chinese FDA), responsible for new drug evaluation, imported drug evaluation and biological products standardization. He is also editor of several keynote National Journals, and scientific consultant of the Amersham Biosciences (China) Limited.

Dr. Arthur Weiss received his M.D. and Ph.D. degrees at the University of Chicago, and later did his postdoctoral work at the Swiss Institute for Experimental Cancer Research, Lausanne. He joined UCSF as a faculty member in 1985, and is the chief of Rheumatology/Clinical Immunology Division. He is also the Ephraim P. Engleman Distinguished Professor of Rheumatology and Professor of Medicine and of Microbiology and Immunology at UCSF. As an investigator of Howard Hughes Medical Institute, he is well known for his great contributions in the fields of activation of T lymphocytes and transplantation immunology. He serves on the scientific advisory boards of many biomedical firms in US.

Dr. Yue Xiong is now the Associate Professor, Department of Biochemistry & Biophysics, The University of North Carolina at Chapel Hill, he is also the member of Program in Molecular Biology & Biotechnology, Lineberger Comprehensive Cancer Center, the University of North Carolina at Chapel Hill. He received his Ph.D. from the department of Biology, the University of Rochester, He did postdoctoral work in Howard Hughes Medical Institute. He is an expert in Mammalian Cell Cycle Control and Tumor Suppression; he has more than 60 publications on famous Journals like Cell and Science.